Latest Biotech News

Bionova Scientific entered a manufacturing alliance with Syenex to expand global access to plasmid DNA for genetic medicines and next‑generation delivery systems. Bionova will serve as Syenex’s...

Boltz launched as a public‑benefit corporation with $28 million in seed funding to democratize AI platforms for drug discovery and biomolecular design. Built by MIT CSAIL alumni and led by CEO...

Media reports say Merck is in talks to acquire Revolution Medicines in a potential $28–32 billion deal, a story that has fueled speculation about consolidation to refill oncology pipelines ahead...

Amgen agreed to acquire Dark Blue Therapeutics and its discovery platform for targeted degradation, including lead candidate DBT‑3757, in a transaction valued at $840 million. Dark Blue’s...

Aktis Oncology priced an upsized initial public offering and raised roughly $318 million, opening trading as one of the first biopharma IPOs of 2026. The company plans to fund phase 1b programs...

Eikon Therapeutics filed for an initial public offering, positioning itself as a bellwether for whether the biotech equity market can sustain a renewed IPO cadence. The filing reveals Eikon's...

Krystal Biotech disclosed early clinical proof‑of‑concept data for a mutation‑agnostic cystic fibrosis gene therapy and said it plans to move directly into a pivotal trial. The company reported...

A pivotal phase 3 trial reported that Lucerastat, an oral therapy, showed efficacy signals in patients with Fabry disease. The results detail clinical endpoints and safety observations that...

Phanes Therapeutics presented phase 2 data at ASCO‑GI showing spevatamig (PT886), an anti‑CLDN18.2/CD47 bispecific antibody, produced encouraging responses when added to chemotherapy in first‑line...

Boltz PBC, spun out of MIT CSAIL by developers of the Boltz series models, launched with a $28 million seed round led by Amplify, a16z and Zetta to commercialize open‑science AI platforms for...

A new wave of personalized gene‑editing ventures has emerged to exploit evolving regulatory pathways for bespoke therapies. Aurora Therapeutics, backed by Menlo Ventures and co‑founded by CRISPR...

Media reports indicate Merck is in talks to acquire Revolution Medicines for an offer in the $28–32 billion range, joining other potential bidders. Revolution’s late‑stage RAS pathway assets,...

AirNexis Therapeutics closed a $200 million series A and secured exclusive rights outside China to HSK39004 (AN01), a PDE3/4 inhibitor for COPD from Haisco Pharmaceutical Group. The deal includes...

The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council (BIC) to improve capital access for emerging biotech companies and to advise on policies that affect early‑stage...

Aktis Oncology raised $318 million in an upsized initial public offering on Jan. 9, 2026, selling 17.65 million shares at $18 apiece. The Boston-based developer, backed by prior private financings...

Palo Alto-based AirNexis Therapeutics closed a $200 million Series A and acquired rights to Haisco’s inhaled PDE3/4 candidate HSK39004 (AN01) outside China, paying $40 million upfront and giving...

Boltz PBC launched out of MIT CSAIL with a $28 million seed round led by Amplify, a16z and Zetta to commercialize an open-science AI stack for molecular structure prediction and therapeutic...

Illumina named former NHGRI director Eric Green chief medical officer, effective Feb. 2, 2026. Green, who led the National Human Genome Research Institute for 16 years, joins Illumina to steer the...

The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council to deepen engagement between venture investors and emerging biotech companies. Chaired by Doug Dieter with...

Financial Times reporting indicates Merck is in preliminary talks to acquire Revolution Medicines for roughly $28–32 billion, a move that would bolster access to Revolution’s late‑stage...